Moderna Doubles On Its Cancer Vaccine's 'Landmark Win,' Merck Hits Record High

Shares of Moderna soared on Wednesday, doubling in value following positive results from a late-stage study of their cancer vaccine, developed in partnership with Merck. The vaccine showed promising results in patients with melanoma, leading to a significant increase in Moderna's stock price. This success also contributed to Merck reaching a record high in its stock value. The news was referred to as a "landmark win" for Moderna, highlighting the importance and impact of this development in the medical and pharmaceutical industry.